Vertex Pharmaceuticals Target Price $300 - Live Trading News
Vertex Pharmaceuticals Target Price $300 Headline News
50 Northern Ave, Boston, Massachusetts, US. | Sector: Manufacturing | Exchange: NASDAQ/NGS (GLOBAL SELECT MARKET) | Web: https://www.vrtx.com/
Vertex Pharmaceuticals Target Price $300 Headline News
Vertex Pharmaceuticals is looking to acquire “mid- and late-stage assets” to bolster its current research pipeline, CEO Reshma Kewalramani said.
(Vertex Pharmaceuticals) BOSTON--(BUSINESS WIRE)--Jan. 7, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.
RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for SYMKEVI® (tezacaftor/ivacaftor)
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) shares have come under selling pressure recently, given investor concern regarding diversity in the pipeline for this cystic fibrosis-focused biopha
Sanford C. Bernstein started coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report issued on Friday, The Fly reports. The brokerage set an “outperform” rating and a $275.00 p
After a year of hesitation in the face of pending cost control guidelines, Vertex Pharmaceuticals has submitted Trikafta to Health Canada for approval - now the hard work begins, writes Jeremie Saunde
(Vertex Pharmaceuticals) BOSTON--(BUSINESS WIRE)--Nov. 13, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it has been notified of an unsolicited